Education
About Us
Working with TipRanks
Follow Us
Predictive Oncology Inc (POAI)
NASDAQ:POAI
Top Page
Predictive Oncology
(NASDAQ:POAI)
Rating:41Neutral
Price Target:
$1.00
▲( 11.11% Upside)
Positive Factors
Technology
The proprietary AI platform PEDAL has demonstrated the potential to identify biomarkers in cancer patients, making it an attractive licensing target.
Negative Factors
Financial Performance
Predictive Oncology reported lower than expected revenue for 3Q24, indicating potential financial challenges.
Strategic Uncertainty
The company is undergoing a strategic review, which includes evaluating alternatives like a sale of the company or its assets, creating uncertainty.
Predictive Oncology (POAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.72M
Dividend YieldN/A
Average Volume (3M)185.99K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-31.31%
EPS Growth49.27%
CountryUS
Employees23
SectorHealthcare
Sector Strength40
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.34
Shares Outstanding8,931,621
10 Day Avg. Volume364,158
30 Day Avg. Volume185,986
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-52.98
Price to Sales (P/S)0.00
P/FCF Ratio-1.13
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit17.07
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Predictive Oncology Business Overview & Revenue Model
Company DescriptionPredictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
How the Company Makes MoneyPredictive Oncology makes money through a diversified revenue model centered around its advanced biotechnology offerings. The company generates income primarily by providing its proprietary AI-driven platforms to healthcare institutions and pharmaceutical companies. These platforms facilitate drug discovery and optimize treatment plans by analyzing vast amounts of genomic and clinical data. Additionally, Predictive Oncology engages in strategic partnerships and collaborations with leading biotech and pharmaceutical firms, which further contribute to its revenue streams. The company's business model is bolstered by licensing agreements and service contracts, allowing access to its expansive database and predictive analytics tools. These partnerships and agreements are crucial in driving the company's growth and expanding its market reach.
Predictive Oncology Financial Statement Overview
Summary
Predictive Oncology faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The company must address operational inefficiencies and stabilize its financial position.Income Statement
The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.35
Negative
Balance Sheet
The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.25
Negative
Cash Flow
Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.35M | 1.62M | 1.78M | 1.51M | 1.42M | 1.25M | Gross Profit |
| 496.51K | 797.68K | 1.15M | 1.00M | 933.66K | 805.08K | EBIT |
| -9.91M | -10.94M | -14.08M | -15.27M | -13.47M | -666.27K | EBITDA |
| -9.17M | -10.16M | -13.18M | -13.95M | -12.13M | -11.46M | Net Income Common Stockholders |
| -8.45M | -12.20M | -13.98M | -36.21M | -19.66M | -37.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.09M | 734.67K | 8.73M | 22.07M | 28.20M | 678.33K | Total Assets |
| 5.87M | 4.97M | 14.42M | 25.73M | 43.77M | 13.06M | Total Debt |
| 1.92M | 2.13M | 2.86M | 180.32K | 879.33K | 5.87M | Net Debt |
| -1.17M | 1.40M | -5.87M | -21.89M | -27.32M | 5.20M | Total Liabilities |
| 6.01M | 5.18M | 6.15M | 3.97M | 3.51M | 10.42M | Stockholders Equity |
| -145.80K | -202.61K | 8.27M | 21.77M | 40.27M | 2.64M |
| Cash Flow | Free Cash Flow | ||||
| -8.55M | -10.98M | -13.49M | -12.85M | -13.17M | -12.62M | Operating Cash Flow |
| -8.54M | -10.97M | -13.19M | -12.37M | -12.21M | -12.26M | Investing Cash Flow |
| 618.52K | -9.51K | -302.37K | -475.70K | -10.61M | -167.46K | Financing Cash Flow |
| 6.55M | 3.94M | 148.90K | 6.72M | 50.34M | 12.95M |
Predictive Oncology Technical Analysis
Negative
0.90
Price Trends
1.12
Negative
1.24
Negative
1.02
Negative
Market Momentum
-0.03
Positive
37.45
Neutral
5.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POAI, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.12, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.45 is Neutral, neither overbought nor oversold. The STOCH value of 5.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POAI.
Predictive Oncology Risk Analysis
Predictive Oncology disclosed 41 risk factors in its most recent earnings report. Predictive Oncology reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Predictive Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
49 Neutral | $9.87M | ― | -80.71% | ― | -2.06% | 49.72% | |
45 Neutral | $22.32M | ― | -62.82% | ― | 115.94% | 17.42% | |
44 Neutral | $14.86M | ― | -138.80% | ― | -14.41% | -549.88% | |
43 Neutral | $19.43M | ― | -25.89% | ― | -16.05% | -195.28% | |
41 Neutral | $8.72M | ― | -504.16% | ― | -31.31% | 49.27% | |
| $4.13M | ― | -75.14% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
POAI
Predictive Oncology
0.90
-1.18
-56.73%
HBIO
Harvard Bioscience
0.37
-2.81
-88.36%
RVP
Retractable Technologies
0.65
-0.29
-30.85%
EKSO
EKSO BIONICS
0.30
-0.90
-75.00%
NXGL
NexGel Inc
2.18
0.08
3.81%
STSS
Sharps Technology, Inc.
3.83
-3,411.01
-99.89%
Predictive Oncology Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q2-2024)
| % Change Since: -15.89%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in AI-driven biomarker discovery, strategic partnerships, and cost reduction initiatives, despite a decline in quarterly revenue and consolidation of non-profitable operations.Q2-2024 Updates
Positive Updates
Successful Retrospective Ovarian Cancer Study
Completion of a multiyear ovarian cancer study with UPMC Magee-Womens Hospital, expanding AI capabilities to discover novel biomarkers for oncology.
Launch of 3D Cell Culture Technology
Introduction of a novel 3D cell culture technology that mimics human tissue architecture more closely, enhancing drug candidate testing and reducing development costs.
ACE Initiative and Collaboration
First collaboration with the University of Michigan under the ACE program, providing access to a large library of natural product drug candidates.
Cost Reduction Initiative
Strategic cost reduction measures, including consolidation of operations from Birmingham to Pittsburgh, expected to reduce annual cash usage by $2.5 million.
Capital Raises
Raised $5.0 million through capital raises to bolster cash balance and extend runway.
Negative Updates
Revenue Decline
Decrease in revenue to $279,000 for Q2 2024 from $490,000 in Q2 2023, primarily from the Egan operating segment.
Birmingham Operations Consolidation
Consolidation of Birmingham operations due to lack of profitability, with the segment generating a net loss of $2.0 million in 2023.
Cash and Equity Reduction
Reduction in cash and cash equivalents to $5.3 million and stockholders' equity to $4.1 million as of June 30, 2024, compared to $8.7 million and $8.3 million respectively as of December 31, 2023.
Company Guidance
During the Predictive Oncology Second Quarter 2024 Earnings Call, the company provided guidance on several strategic initiatives and financial metrics. Key highlights included the completion of a multiyear ovarian cancer study, which utilized data from 235 patients and resulted in the training of 160 predictive models with high accuracy. The company also launched a novel 3D cell culture technology and reported progress in its ACE initiative, forming a collaboration with the University of Michigan. Financially, Predictive Oncology reported a net loss of $3.2 million for the quarter, with a revenue of $279,000, compared to $490,000 in the previous year. They highlighted a strategic cost reduction initiative expected to save approximately $2.5 million annually, and capital raises totaling $5.0 million to bolster their cash position.Predictive Oncology Corporate Events
M&A TransactionsBusiness Operations and Strategy
Predictive Oncology Ends Merger Talks with Renovaro
Neutral
Apr 7, 2025
Predictive Oncology Inc. announced that it has discontinued discussions with Renovaro Inc. regarding a proposed merger, clarifying that no binding agreement was ever reached despite contrary claims by Renovaro. The letter of intent for the merger, initially signed on January 1, 2025, and extended on February 28, 2025, expired on March 31, 2025, leaving Predictive Oncology with no further obligations to Renovaro. The company remains focused on advancing its core business in AI-driven drug discovery and development.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.